Clinical trial
An Observational, Prospective Cohort Study to Evaluate the Safety and Efficacy of Remsima™ in Patients With Crohn's Disease (CD) or Ulcerative Colitis (UC)
NCT02326155 is registered in ClinicalTrials.gov with Celltrion as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Observational, Prospective Cohort Study to Evaluate the Safety and Efficacy of Remsima™ in Patients With Crohn's Disease (CD) or Ulcerative Colitis (UC)
- Lead sponsor
- Celltrion
- Phase
- Observational
- Overall status
- Terminated
- Start date
- December 8, 2014
- Completion date
- February 28, 2020
- Enrollment
- 470 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
crohn's disease, ulcerative colitis